Apixaban Compared With Warfarin for Stroke Prevention in Atrial Fibrillation Implications of Time in Therapeutic Range

被引：11
作者：
Gallego, Pilar [1 ,2 ]
Antonio Vilchez, Juan [1 ,3 ,4 ]
Lane, Deirdre A. [1 ]
机构：
[1] Univ Birmingham, City Hosp, Ctr Cardiovasc Sci, Birmingham B18 7QH, W Midlands, England
[2] Morales Meseguer Univ Hosp, Dept Hematol & Clin Oncol, Murcia, Spain
[3] Hosp Univ Virgen de la Arrixaca, Dept Cardiol, Murcia, Spain
[4] Hosp Univ Virgen de la Arrixaca, Dept Clin Anal, Murcia, Spain
来源：
CIRCULATION | 2013年 / 127卷 / 22期
关键词：
Editorials; anticoagulants; apixaban; atrial fibrillation; time in therapeutic range; warfarin; NORMALIZED RATIO CONTROL; ANTICOAGULATION CONTROL; ORAL ANTICOAGULANT; EFFICACY; OUTCOMES; QUALITY; SAFETY;
D O I：
10.1161/CIRCULATIONAHA.113.003132
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2163 / 2165
页数：3
相关论文
共 50 条
  • [41] Cost Effectiveness of Apixaban versus Warfarin or Aspirin for Stroke Prevention in Patients with Atrial Fibrillation: A Greek Perspective
    Athanasakis, Kostas
    Boubouchairopoulou, Nadia
    Karampli, Eleftheria
    Tarantilis, Filippos
    Savvari, Paraskevi
    Bilitou, Aikaterini
    Kyriopoulos, John
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2017, 17 (02) : 123 - 133
  • [42] Suboptimal Anticoagulant Management in Japanese Patients with Nonvalvular Atrial Fibrillation Receiving Warfarin for Stroke Prevention
    Hirano, Teruyuki
    Kaneko, Hirokazu
    Mishina, Sari
    Wang, Feng
    Morita, Satoshi
    JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, 2017, 26 (10) : 2102 - 2110
  • [43] Apixaban: A New Factor Xa Inhibitor for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation
    Lam, Sum
    CARDIOLOGY IN REVIEW, 2013, 21 (04) : 207 - 212
  • [44] Cost-effectiveness analysis of apixaban compared to other direct oral anticoagulants for prevention of stroke in Austrian atrial fibrillation patients
    Walter, Evelyn
    Voit, Marco
    Eichhober, Gerald
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2021, 21 (02) : 265 - 275
  • [45] Standard and reduced doses of dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: a nationwide cohort study
    Staerk, L.
    Gerds, T. A.
    Lip, G. Y. H.
    Ozenne, B.
    Bonde, A. N.
    Lamberts, M.
    Fosbol, E. L.
    Torp-Pedersen, C.
    Gislason, G. H.
    Olesen, J. B.
    JOURNAL OF INTERNAL MEDICINE, 2018, 283 (01) : 45 - 55
  • [46] Cost-Effectiveness Analysis of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation in Taiwan
    Chieh-Yu Liu
    Hui-Chun Chen
    Clinical Drug Investigation, 2017, 37 : 285 - 293
  • [47] Echocardiographic Risk Factors for Stroke and Outcomes in Patients With Atrial Fibrillation Anticoagulated With Apixaban or Warfarin
    Vinereanu, Dragos
    Lopes, Renato D.
    Mulder, Hillary
    Gersh, Bernard J.
    Hanna, Michael
    de Barros e Silva, Pedro G. M.
    Atar, Dan
    Wallentin, Lars
    Granger, Christopher B.
    Alexander, John H.
    STROKE, 2017, 48 (12) : 3266 - 3273
  • [48] Temporal trends of time in therapeutic range and incidence of cardiovascular events in patients with non-valvular atrial fibrillation
    Pastori, Daniele
    Farcomeni, Alessio
    Saliola, Mirella
    Del Sole, Francesco
    Pignatelli, Pasquale
    Violi, Francesco
    Lip, Gregory Y. H.
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2018, 54 : 34 - 39
  • [49] Renal Function, Time in Therapeutic Range and Outcomes in Warfarin-Treated Atrial Fibrillation Patients: A Retrospective Analysis of Nationwide Registries
    Bonde, Anders Nissen
    Lip, Gregory Y. H.
    Kamper, Anne-Lise
    Staerk, Laila
    Torp-Pedersen, Christian
    Gislason, Gunnar
    Olesen, Jonas Bjerring
    THROMBOSIS AND HAEMOSTASIS, 2017, 117 (12) : 2291 - 2299
  • [50] Improvement of time in therapeutic range with warfarin by pharmaceutical intervention
    Viquez-Jaikel, Alvaro
    Hall-Ramirez, Victoria
    Ramos-Esquivel, Allan
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2017, 39 (01) : 41 - 44
12345